Triple glucagon/GLP-1/GIP receptor agonist

Patent metadata

Field	Value
Publication number	US-10370426-B2
Application number	US-201816023994-A
Country	US
Kind code	B2
Filing date	Jun 29, 2018
Priority date	Dec 31, 2015
Publication date	Aug 6, 2019
Grant date	Aug 6, 2019

Abstract

The present invention relates to a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors and uses thereof.

First claim

The invention claimed is:

1. An isolated peptide having activities to a glucagon receptor, a glucagon-like peptide-1 (GLP-1) receptor, and a glucose-dependent insulinotropic polypeptide (GIP) receptor,
wherein the isolated peptide comprises the amino acid sequence of the following Formula (1):

(SEQ ID NO: 103)

Xaa1-Xaa2-Xaa3-Gly-Thr-Phe-Xaa7-Ser-Asp-Xaa10-Ser-

Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17-Xaa18-Xaa19-

Xaa20-Xaa21-Phe-Xaa23-Xaa24-Trp-Leu-Xaa27-Xaa28-

Xaa29-Xaa30-R1

wherein, in Formula (1),
Xaa1 is His, 4-imidazoacetyl (CA), or Tyr;
Xaa2 is α-methyl-glutamic acid, or aminoisobutyric acid (Aib);
Xaa3 is Gln;
Xaa7 is Thr;
Xaa10 is Tyr;
Xaa12 is Lys;
Xaa13 is Tyr, Ala, or Cys;
Xaa14 is Leu or Met;
Xaa15 is Cys, Asp, or Glu;
Xaa16 is Gly or Glu;
Xaa17 is Gln, Arg, Ile, Glu, Cys, or Lys;
Xaa18 is Ala, Arg, or His;
Xaa19 is Ala, Gln, or Cys;
Xaa20 is Lys;
Xaa21 is Glu, Gln, Cys, or Asp;
Xaa23 is Ile or Val;
Xaa24 is Ala, Gln, Cys, or Asn;
Xaa27 is Leu or Lys;
Xaa28 is Cys, Ala, or Asp;
Xaa29 is Cys, Gly, Gln, Thr, Glu, or His;
Xaa30 is Cys, Gly, Lys, or His, or is absent; and
R1 is Cys, GKKNDWKHNIT (SEQ ID NO: 106), m-SSGAPPPS-n (SEQ ID NO: 107), or m-SSGQPPPS-n (SEQ ID NO: 108), or is absent;
wherein
m is -Cys-, -Pro-, or -Gly-Pro-; and
n is -Cys-, -Gly-, -Ser-, or -His-Gly-, or is absent.

2. The isolated peptide of claim 1 , wherein R1 is Cys, GKKNDWKHNIT (SEQ ID NO: 106), CSSGQPPPS (SEQ ID NO: 109), GPSSGAPPPS (SEQ ID NO: 110), GPSSGAPPPSC (SEQ ID NO: 111), PSSGAPPPS (SEQ ID NO: 112), PSSGAPPPSG (SEQ ID NO: 113), PSSGAPPPSHG (SEQ ID NO: 114), PSSGAPPPSS (SEQ ID NO: 115), PSSGQPPPS (SEQ ID NO: 116), or PSSGQPPPSC (SEQ ID NO: 117), or is absent.

3. The isolated peptide of claim 1 , wherein the isolated peptide is selected from the group consisting of SEQ ID NOS: 21 to 23, 30 to 32, 34, 42, 43, 50 to 52, 56, 58, 64 to 71, 73 to 78, 82, 86, 89, 93, and 95 to 102.

4. The isolated peptide of claim 3 , wherein the isolated peptide is selected from the group consisting of SEQ ID NOS: 21, 22, 23, 31, 32, 42, 43, 50, 64 to 71, 73 to 77, and 96 to 102.

5. The isolated peptide of claim 1 ,
wherein, in Formula (1),
Xaa13 is Ala, Tyr, or Cys;
Xaa15 is Asp or Glu;
Xaa17 is Gln, Arg, Cys, or Lys;
Xaa18 is Ala, Arg, or His;
Xaa21 is Cys, Glu, Gln, or Asp;
Xaa23 is Ile or Val;
Xaa24 is Cys, Gln, or Asn;
Xaa28 is Cys or Asp;
Xaa29 is Gln, Cys, or His; and
Xaa30 is Cys, Lys, or His.

6. The isolated peptide of claim 1 ,
wherein, in Formula (1),
Xaa1 is His or 4-imidazoacetyl;
Xaa13 is Ala or Cys;
Xaa14 is Met;
Xaa15 is Asp;
Xaa16 is Glu;
Xaa17 is Ile or Lys;
Xaa18 is Ala or His;
Xaa19 is Gln or Cys;
Xaa20 is Lys;
Xaa21 is Asp;
Xaa23 is Val;
Xaa24 is Asn;
Xaa28 is Ala;
Xaa29 is Gln or Thr; and
Xaa30 is Cys or Lys, or is absent.

7. A pharmaceutical composition comprising the peptide of claim 1 .

8. A method of treating metabolic syndrome comprising administering the peptide according to claim 1 to a subject in need thereof,
wherein the metabolic syndrome comprises impaired glucose tolerance, hypercholesterolemia, dyslipidemia, obesity, diabetes, hypertension, arteriosclerosis due to dyslipidemia, atherosclerosis, arteriosclerosis, or coronary heart disease.

9. The isolated peptide of claim 1 , wherein the isolated peptide comprises the amino acid sequence of the following Formula (3):

(SEQ ID NO: 105)

Xaa1-Xaa2-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-

Xaa13-Leu-Asp-Glu-Xaa17-Xaa18-Xaa19-Lys-Xaa21-Phe-

Val-Xaa24-Trp-Leu-Leu-Xaa28-Xaa29-Xaa30-Xaa31-Ser-

Ser-Gly-Gln-Pro-Pro-Pro-Ser-Xaa40

wherein, in Formula (3),
Xaa1 is His or Tyr;
Xaa2 is a-methyl-glutamic acid or aminoisobutyric acid (Aib);
Xaa13 is Ala, Tyr, or Cys;
Xaa17 is Arg, Cys, or Lys;
Xaa18 is Ala or Arg;
Xaa19 is Ala or Cys;
Xaa21 is Glu or Asp;
Xaa24 is Gln or Asn;
Xaa28 is Cys or Asp;
Xaa29 is Cys, His, or Gln;
Xaa30 is Cys or His;
Xaa31 is Pro or Cys; and
Xaa40 is Cys or is absent.

10. The isolated peptide of claim 9 , wherein the isolated peptide is selected from the group consisting of SEQ ID NOS: 21, 22, 42, 43, 50, 64, 66, 67, 70, 71, 76, 77, 96, 97 and 100.

11. The isolated peptide according to claim 9 , wherein, in Formula (3), the 16th amino acid and the 20th amino acid from the N-terminus together form a ring.

12. The isolated peptide of claim 9 , wherein Xaa1 is Tyr.

13. A pharmaceutical composition comprising the peptide of claim 9 .

14. A method of treating metabolic syndrome comprising administering the peptide according to claim 9 to a subject in need thereof,
wherein the metabolic syndrome comprises impaired glucose tolerance, hypercholesterolemia, dyslipidemia, obesity, diabetes, hypertension, arteriosclerosis due to dyslipidemia, atherosclerosis, arteriosclerosis, or coronary heart disease.

15. An isolated peptide selected from the group consisting of SEQ ID NOS: 24, 27-29, 36, 37, 39, 53, 55, 72, 79, 81, and 88.

16. The isolated peptide of claim 15 , wherein the peptide is selected from the group consisting of SEQ ID NOS: 24, 29, 36, 37, 81, and 88.

Assignees

• Hanmi Pharm Ind Co Ltd

Inventors

• Oh Euh Lim
• Lee Jong Suk
• Park Young Jin
• Lim Chang Ki
• Jung Sung Youb
• Kwon Se Chang

Classifications

• A61K38/26 Primary

  Glucagons · CPC title

• A61K39/3955

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title